
|Articles|December 17, 2013
- Melanoma (Issue 1)
- Volume 1
- Issue 1
The Outlook for BRAF Inhibitors in Melanoma
Author(s)Antoni Ribas, MD, PhD
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Advertisement
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Read more about BRAF inhibitors for the treatment of melanoma and
Articles in this issue
over 12 years ago
Two BRAF Fusions Discovered in Some Pan-Negative Melanomasover 12 years ago
Understanding the Biologic Pathways in Basal Cell Carcinomaover 12 years ago
Advances in Metastatic Melanomaover 12 years ago
Targeted Therapies in Basal Cell Carcinomaover 12 years ago
The Treatment of Melanoma With Emerging Targeted TherapiesAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5

































